Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757713 · ClinicalTrials.gov registry record · Phase 4
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
A Phase 4 study of Diabetes Mellitus, Type 1, sponsored by Sanofi.
- Active
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 10
- Study locations
NCT05757713 is a Phase 4 study of Diabetes Mellitus, Type 1 that is active but no longer recruiting, run by Sanofi. The registered enrollment target is 20 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT05757713, a Phase 4 study of Diabetes Mellitus, Type 1, is active but no longer recruiting, sponsored by Sanofi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
Conditions Studied
Interventions
- BIOLOGICAL teplizumab
Study Locations (10)
California
- UCSF Medical Center Site Number : 107 - San Francisco
Colorado
- Barbara Davis Center for Diabetes Site Number : 102 - Aurora
Connecticut
- Yale University School of Medicine Site Number : 101 - New Haven
Georgia
- Centricity Research Site Number : 104 - Columbus
Indiana
- Indianapolis University Health Riley Hospital for Children Site Number : 110 - Indianapolis
New York
- UBMD Pediactrics Site Number : 105 - Buffalo
Pennsylvania
- Children's Hospital of Philadelphia Site Number : 108 - Philadelphia
South Dakota
- Sanford Diabetes and Thyroid Clinic Site Number : 106 - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2026-08-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05757713
The ClinicalTrials.gov registry entry for NCT05757713 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (98% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 1 intervention - of which teplizumab is the first listed.
NCT05757713 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05757713 about?
NCT05757713 is a clinical study titled "Teplizumab in Pediatric Stage 2 Type 1 Diabetes". The purpose of this study is to assess the safety and pharmacokinetics (PK) of teplizumab in participants with Stage 2 type 1 diabetes who are \<8 years of age.
What is the current status of trial NCT05757713?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-07-25. Estimated completion is 2026-08-27.
What conditions does trial NCT05757713 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT05757713?
The interventions under investigation include: teplizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05757713?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757713 being conducted?
This trial has 10 study locations across California, Colorado, Connecticut, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin for Preeclampsia Prevention in Pregnant Women With Type 1 Diabetes Mellitus
ACTIVE NOT RECRUITING · Phase 4
-
Afrezza® Dosing Optimization Study
COMPLETED · Phase 4
-
Sitagliptin Dose Determination Study
COMPLETED · Phase 4
-
Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
COMPLETED · Phase 4
-
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
COMPLETED · Phase 4
-
Comparison of Glycemic Control Achieved With 2 Different Needles
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.